Maximum standardized uptake value on positron emission tomography/computed tomography predicts clinical outcome in patients with relapsed or refractory diffuse large B-cell lymphoma
Blood Research
; : 97-102, 2015.
Article
de En
| WPRIM
| ID: wpr-184127
Bibliothèque responsable:
WPRO
ABSTRACT
BACKGROUND: Few clinical studies have clarified the prognostic factors that affect clinical outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after immunochemotherapy. METHODS: A total of 158 patients with relapsed or refractory DLBCL were enrolled. All patients underwent positron emission tomography/computed tomography (PET/CT) before and after salvage therapy. All enrolled patients previously received the ifosfamide, carboplatin, and etoposide regimen. Clinical outcomes were compared according to several factors (age > or = 65 years, low age-adjusted International Prognostic Index [aa-IPI], maximum standardized uptake value [SUVmax] or =12 months, complete response after salvage therapy). A low aa-IPI, SUVmax or = 12 months were independent prognostic factors for survival. RESULTS: In univariate analysis and multivariate analysis, SUVmax below 6.0 (P<0.001 for progression-free survival (PFS), P<0.001 for overall survival (OS)) and low aa-IPI (P<0.001 for PFS, P<0.001 for OS) were independent prognostic factors associated with favorable outcome. CONCLUSION: The aa-IPI and initial SUVmax were powerful prognostic factors in patients with relapsed or refractory DLBCL.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Récidive
/
Analyse multifactorielle
/
Carboplatine
/
Lymphome B
/
Thérapie de rattrapage
/
Survie sans rechute
/
Tomographie par émission de positons
/
Électrons
/
Étoposide
/
Tomographie par émission de positons couplée à la tomodensitométrie
Type d'étude:
Prognostic_studies
Limites du sujet:
Humans
langue:
En
Texte intégral:
Blood Research
Année:
2015
Type:
Article